Can­cer biotech ends tri­al, search­es for sale or oth­er route

Aileron Ther­a­peu­tics has scrapped its tri­al, laid off most em­ploy­ees and is search­ing for a merg­er part­ner or oth­er strate­gic al­ter­na­tive.

The Boston biotech said a re­view of ini­tial da­ta from a Phase Ib tri­al showed pa­tients “ex­pe­ri­enced se­vere neu­trope­nia (Grade 4) and alope­cia,” com­mon­ly known as hair loss. Aileron was test­ing its drug AL­RN-6924 in pa­tients with p53-mu­tat­ed breast can­cer. The open-la­bel study was test­ing neoad­ju­vant or ad­ju­vant treat­ment with do­c­etax­el, dox­oru­bicin, and cy­clophos­phamide, al­so known as “TAC” chemother­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER